Abstract. The objective of this study was to elucidate the clinical characteristics of uncommon head and neck malignancies, such as non-squamous cell carcinoma (SCC), in order to improve patient outcomes. A total of 463 head and neck malignancies were retrospectively analyzed, with 43 cases (9.3%) diagnosed as non-SCC. The overall survival rate of patients with adenoid cystic carcinoma was significantly worse compared to that of patients with SCC. The 5-year survival rates were <50% for patients with malignant melanoma, adenocarcinoma, small-cell carcinoma and sarcomas. Distant metastasis to the lung was frequently observed in cases with a poor outcome. Non-SCC malignancies treated without surgery were associated with a worse outcome. Some non-SCC patients had a poor prognosis and distant metastasis was associated with an unsatisfactory outcome. Timely treatment and control of distant metastasis are essential and surgical treatment should be prioritized in non-SCC cases to improve patient outcomes.
The average age of the men was 61.6 years (range, 13-85 years) and that of the women 62.1 years (range, 29-94 years). In total, 43 cases (9.3%) were confirmed as non-SCC (Fig. 1A) . Of the non-SCC cases, 20 (46.5%) were male (Fig. 1B) and the overall average age at the first visit was 61.8 years (range, 13-92 years). Of the 420 SCC cases, 246 (58.6%) were male ( Fig. 1C ) and the average age was 66.2 years (range, 21-94 years). The age distribution analysis revealed that a higher number of SCC patients were in the age range of 50-80 years. However, the non-SCC group included younger patients (aged <30 years) as well as older patients (Fig. 2) . These data indicate that the non-SCC group included more women compared to the SCC group and that there is a wider age distribution trend in the non-SCC compared to the SCC group.
Among the SCC cases, the tongue was the most frequent primary site, followed by the mandible. However, non-SCCs occurred most frequently in the palate and maxilla (Fig. 3) .
Pathological classification. The pathological classification revealed that ACC (14 cases) and haematolymphoid tumours (16 cases) were the most frequently encountered malignancies (Table I) . Less frequent neoplasms included mucoepidermoid carcinoma (2 cases), basal cell adenocarcinoma (1 case), adenocarcinoma (1 case), malignant ameloblastoma (1 case), small-cell carcinoma (1 case), mucosal malignant melanoma (4 cases), rhabdomyosarcoma (2 cases) and synovial sarcoma (1 case). Patients with haematolymphoid tumours were referred to the Division of Internal Medicine for treatment. Therefore, ACC was the most frequently encountered non-SCC malignancy treated at our Department.
Treatment and outcomes. Surgery was mainly selected as the primary treatment, except for malignant lymphoma, with chemotherapy or radiotherapy administered as necessary. Conversely, malignant lymphoma was mainly treated with chemotherapy and/or radiotherapy (Table II) . In cases with local recurrence or distant metastasis, additional surgery, chemotherapy and/or radiotherapy were administered.
The correlation between surgical treatment and outcome was analyzed in non-SCC cases, except for malignant lymphoma. Four patients did not undergo surgery and they all succumbed to the disease within 5 years (Table III) . Conversely, 14 of the 19 patients (74%) who underwent surgery survived for >5 years. The 5-year survival rate was significantly higher among patients who underwent surgery compared to those who did not (P=0.014) (Table IV) . 
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The 5-year survival rates were ≤50% for patients with adenocarcinoma, small-cell carcinoma, mucosal malignant melanoma, rhabdomyosarcoma and synovial sarcoma (Table I) .
Salivary gland carcinomas. One ACC patient refused treatment. The remaining 13 ACC patients underwent surgery and additionally received radiotherapy or chemotherapy, as required. Among the 5 surviving ACC patients, 2 have survived for >5 years, while 6 of the 9 deceased ACC patients survived for >5 years after treatment. Thus, 8 of the 11 cases (73%) remained alive at the 5-year observation time point (Table I) . Subsequently, the survival rate decreased significantly, resulting in a 10-year cumulative survival rate of 38% (Fig. 4) . The cumulative survival rates at the 5-year observation time point between ACC and SCC patients were similar. However, the subsequent decrease in the ACC was more noticeable compared to the decrease in the SCC survival rate (P=0.004; Fig. 4 ).
Distant metastasis was not observed in any of the surviving patients. Distant metastases were observed in 9 of the 14 ACC cases, 6 of which occurred within 3 years following primary treatment (Fig. 5 ). Lung metastasis occurred in all patients with metastasis (Table V) . The overall average survival duration following local recurrence or distant metastasis was 4.1 years and the survival duration was 3.4 and 6.4 years when treated with and without radiotherapy, respectively (Fig. 6 ). Distant metastasis was observed in 22 of the 420 SCC patients; thus, ACC exhibited a significantly higher incidence of distant metastasis compared to SCC (P<0.001) ( Table VI) . The ACC patient information is summarized in Table VII to clarify the association between clinicopathological factors and distant metastasis. The data demonstrated that the distant metastasis rate was significantly higher in T3+T4 when compared to that in T1+T2 cases (P=0.021). In addition, distant metastasis occurred in all the patients who experienced regional lymph node metastasis. Distant metastasis was frequently observed in the sinus (100%), submandibular gland (100%) and oral floor (75%), but was comparably rare in the palate (33%) ( Table VII) . There was no significant association between distant metastasis and histological type. In addition, there were 2 cases of mucoepidermoid carcinoma, 1 advanced case of adenocarcinoma and 1 case of basal cell adenocarcinoma. The 2 cases with mucoepidermoid carcinoma were treated with surgery, including neck dissection, and the patients have remained alive for 7 and 11 years, respectively, with no evidence of recurrence or metastasis (Table VIII) . The advanced adenocarcinoma case was staged as T3N2bM0 (Table VI) . The patient underwent surgical tumour resection and neck dissection. Additional treatments, such as adjuvant chemotherapy and radiotherapy were planned; however, neither was administered due to the patient's poor overall condition. After 8 months, multiple lymph node metastases were detected in the neck. The patient did not consent to further treatment and eventually succumbed to the disease 17 months after her first visit.
Haematolymphoid tumours. Three patients underwent surgery, were diagnosed with malignant lymphoma and were referred to the Internal Medicine Department. For the other malignant lymphoma cases, biopsy or image analyses were used for diagnosis and the patients were directly referred to Internal Medicine. All the malignant lymphoma cases were non-Hodgkin lymphomas, with 13 cases of B-cell neoplasms and 3 cases of Table III . Comparison of 5-year survival rate between non-squamous cell carcinomas patients treated with and without surgery. Comparison of cumulative survival rate between non-squamous cell carcinoma (SCC) and SCC patients. The P-value was calculated using the log-rank test. ACC, adenoid cystic carcinoma. natural killer or T-cell (NK/T) neoplasms (Table IX) . Chemotherapy or radiotherapy was the main therapeutic option for patients with malignant lymphoma (Tables II and IX) . At the 5-year observation time point, 5 of the 11 malignant lymphoma cases (45%) had survived ( Table I ). The median observation period for surviving patients and the survival period for deceased patients were 6.0 and 3.6 years, respectively. Of the NK/T-cell lymphoma patients, 2 succumbed to the disease and 1 has remained alive for 5 years without recurrence. The surviving NK/T-cell lymphoma patient is a 28-year-old woman who was treated with radiotherapy (50 Gy) and 3 courses of dexamethasone, etoposide, ifosfamide and carboplatin (DeVIC).
5-year survived patients --------------------------------------------------
Other malignancies. A case of small-cell carcinoma (neuroendocrine type) was treated by surgery (tumour resection and neck dissection) and concurrent chemoradiotherapy, which comprised 5 courses of cisplatin + etoposide (PE) and 1 course of cisplatin + irinotecan (PI), with 66 Gy of radiotherapy (Table VIII) . This malignancy is common in the lung but extremely rare in the head and neck region (11, 12) . Since PE and PI are considered to be the standard treatment for SCC of the lung, they were selected for this case. However, the patient succumbed to the disease 18 months after his first visit. M, male; F, female; R, radiotherapy; C, chemotherapy; S, surgery; ND, regional neck dissection; T, tubular; Cr, cribriform; Sol, solid; 5FU, fluorouracil; CDDP, cisplatin; Submand., submandibular. TNM, tumor node metastasis; A, alive; D, deceased.
Table VI. Comparison of distant metastasis incidence between adenoid cystic carcinoma and squamous cell carcinoma. In total, 4 cases of malignant melanoma were treated (Table X) . All the patients succumbed to the disease at 2, 3, 8 and 10 years after diagnosis. The 2 patients who survived the longest had undergone tumour resection with regional neck dissection, combined with chemotherapy or concurrent chemoradiotherapy. Surgical treatment was suggested to the remaining 2 patients, who experienced a shorter survival. However, both patients refused surgery and opted for chemotherapy or concurrent chemoradiotherapy.
Distant metastasis
A total of 2 rhabdomyosarcoma patients and 1 synovial sarcoma patient visited our Department (Table XI) . The outcomes for the rhabdomyosarcoma cases were poor. The first rhabdomyosarcoma patient was a 13-year-old boy. The CT scan revealed multiple metastases in the lungs, suggesting that surgical treatment was not feasible. Thus, the patient was immediately transferred to the Pediatrics Department for chemotherapy. The patient finally succumbed to respiratory dysfunction 9 months after his first visit. The second rhabdomyosarcoma patient was a 61-year-old woman who was treated with surgery and chemoradiotherapy. The treatment achieved effective control of the local lesion; however, distant lung metastasis occurred and compromised the patient's general condition. It should be noted that both rhabdomyosarcoma patients succumbed to their disease within 2 years after their first visits.
The synovial sarcoma patient was a 66-year-old man treated with surgery. Although there was no evidence of recurrence, the patient died of hepatocellular carcinoma 2 years after surgery.
Discussion
The incidence of SCC is higher compared to that of non-SCC (2), a fact also confirmed by our study (90.7 vs. 9.3%, respectively). In addition, our data revealed that the clinical outcomes of certain non-SCC cases were not satisfactory when compared to those of SCC cases, indicating that, although non-SCCs are minor diseases from the perspective of epidemiology, these cases should be managed carefully. A possible explanation as to why treatment of head and neck non-SCCs is difficult may lie with their low frequency. Therefore, the accumulated clinical observations provided in the present study may be of great value. All clinicians should disclose information on the head and neck non-SCC cases they encounter in order to share this limited information and improve clinical outcomes.
The cumulative survival rates were found to be significantly worse in ACC compared to those in SCC patients (P=0.004; Fig. 4) . The unsatisfactory outcome of ACC may be due to the early and high incidence of distant metastasis. In the present study, 6 metastases occurred within 3 years after primary treatment and all the patients who experienced distant metastasis eventually succumbed to the disease. Conversely, distant metastasis was not observed in any of the surviving cases. The distant metastasis rate of ACC was significantly higher compared to that of SCC (Table VI) . Our data revealed that tumour size is the most significant risk factor for distant metastasis. Therefore, timely diagnosis and treatment are essential in ACC cases. Although no definitive clinical approach for preventing distant metastasis has been established, it was previously reported that surgery with postoperative radiotherapy significantly improved the outcomes (13) . Additionally, Lin et al (14) reported that postoperative radiotherapy reduced the recurrence rate in patients with a negative resection margin. 
Distant metastasis -----------------------------------Clinical factors
Yes ( (n=2) 2 (100) 0 (0) In the present study, the effect of postoperative irradiation on recurrence in margin-negative cases was not confirmed. The overall average survival duration following local recurrence or distant metastasis was 4.1 years, indicating that metastasized tumours progress slowly or secondary treatment may suppress tumour development to a certain extent. It is also crucial to maintain the quality of life following recurrence or distant metastasis in ACC patients. Of the cases with metastasis, 2 out of 9 underwent radiotherapy for distant lesions and the average survival duration was 6.4 years (Fig. 6) . Therefore, radiotherapy for metastatic disease should be considered as the primary therapeutic option. M, male; F, female; C, chemotherapy; R, radiotherapy; S, surgery; DLBCL, diffuse large B-cell lymphoma; B, B-cell neoplasm; MALT, mucosa-associated lymphoid tissue; NK, natural killer; ALCL, anaplastic large-cell lymphoma.
A number of cases with haematolymphoid tumours were also observed. All the cases were non-Hodgkin lymphomas, comprising 13 B-cell neoplasms and 3 NK/T-cell neoplasms. NK/T-cell lymphoma is generally aggressive and is associated with a poor outcome (15, 16) . Of the patients with 3 NK/T-cell lymphoma, 2 succumbed to the disease and 1 has survived for 5 years without any evidence of recurrence. Cyclophosphamide, doxorubicin, vincristine and prednisone therapy followed by radiotherapy is currently the established standard treatment for localized non-Hodgkin lymphoma (17) . However, as the outcome of localized NK/T-cell lymphoma (nasal type) treated with this therapy is not satisfactory, concurrent chemoradiotherapy as a therapeutic option has been investigated in Japan. A phase I/II trial of concurrent chemoradiotherapy (DeVIC and 50 Gy irradiation) for localized nasal NK/T-cell lymphoma was conducted and the authors concluded that this regimen should be recommended as a first-line treatment for this type of malignancy (18) . The surviving NK/T-cell lymphoma patient in our study was a 28-year-old woman who initially presented with a stage I localized lesion in her upper gingiva. The patient was immediately referred to our Department for prompt treatment and received radiotherapy (50 Gy) and 3 courses of DeVIC. These findings indicate that initiating treatment at an early stage is crucial and that concurrent chemoradiotherapy should be recommended hereafter for NK/T-cell lymphomas.
In the present study, there were 4 cases of mucosal malignant melanoma. Two of the patients (50%) exhibited long-term survival; however, all the patients eventually succumbed to their disease. Malignant melanoma of the head and neck is difficult to cure. Of the deceased patients, 2 died within 3 years after treatment, whereas the remaining 2 patients survived for a significantly longer period. A 74-year-old male patient survived for 10 years, despite developing distant metastases in the lung and brain. In addition, a 67-year-old female patient survived disease-free for ~8 years until distant metastasis to her lung and bronchus occurred. Both patients underwent surgery, including neck dissection, indicating that resection of the primary lesion and regional lymph nodes may prolong survival. However, distant metastasis, mainly to the lungs, hampers the management of head and neck malignant melanoma.
Rhabdomyosarcoma is a malignant soft tissue tumour of skeletal muscle origin that is most commonly encountered in the head and neck region (19) . Rhabdomyosarcoma frequently occurs in childhood, particularly in individuals aged <15 years. Indeed, in the present study, of the 2 rhabomyosarcoma patients, 1 was a 13-year-old boy. Both rhabdomyosarcoma patients developed distant lung metastasis and succumbed to their disease within 2 years of their first visits. In a review of sarcomas of the oral and maxillofacial region, Yamaguchi et al (20) reported that 3 of 5 rhabdomyosarcoma cases died within 3 years after treatment and that distant metastasis occurred in the deceased but not in the surviving and disease-free patients. These observations strongly indicate that distant metastasis is a major complication contributing to the poor outcome in patients with rhabdomyosarcoma and malignant melanoma. Overall, the data of the present study indicate that non-SCC patients frequently develop distant metastasis to the lung and that the survival rate was significantly higher in the non-SCC patients who underwent surgery compared to those who did not. Furthermore, we hypothesized that the poor outcomes may be due to the limited amount of clinical information available regarding these rare malignancies. However, the present study was limited by the fact that it was a single-center study with a limited number of non-SCC cases. Therefore, the continued accumulation of information from various clinical trials and other studies is required for improving the clinical outcomes of non-SCCs patients.
In conclusion, our data indicated that non-SCC malignant tumours of the head and neck are relatively rare. However, non-SCC malignant tumours are a clinically significant entity, as their management is generally difficult. Timely treatment and control of distant metastasis are essential and surgical treatment should be prioritized in non-SCC cases in order to improve the outcomes in such patients.
